Saurabh Zanwar1, Jithma Prasad Abeykoon1,2, Prashant Kapoor3,4. 1. Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 2. Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 3. Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. kapoor.prashant@mayo.edu. 4. Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. kapoor.prashant@mayo.edu.
Abstract
PURPOSE OF REVIEW: Recent advances the genomic profiling of patients with Waldenström macroglobulinemia (WM) have led to the identification of novel therapeutic targets in these patients. In this review, we cover the current standard of care and the recently evaluated novel approaches with high potential to be incorporated in the therapeutic armamentarium against WM. RECENT FINDINGS: The MYD88L265P mutation is the most common genomic abnormality in WM, and is encountered in 80-95% of patients, making it an important target for drug development. The success of the first-generation Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, has generated tremendous interest in the study of more selective and potent BTK inhibitors. Additionally, the identification of CXCR4WHIM mutations in up to approximately 40% of patients with WM has fueled research regarding their implication on systemic therapy in WM. In a rapidly advancing field of targeted therapies, the treatment options for patients with WM are expanding as researchers continue to uncover and harness the survival pathways active in this hematologic malignancy.
PURPOSE OF REVIEW: Recent advances the genomic profiling of patients with Waldenström macroglobulinemia (WM) have led to the identification of novel therapeutic targets in these patients. In this review, we cover the current standard of care and the recently evaluated novel approaches with high potential to be incorporated in the therapeutic armamentarium against WM. RECENT FINDINGS: The MYD88L265P mutation is the most common genomic abnormality in WM, and is encountered in 80-95% of patients, making it an important target for drug development. The success of the first-generation Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, has generated tremendous interest in the study of more selective and potent BTK inhibitors. Additionally, the identification of CXCR4WHIM mutations in up to approximately 40% of patients with WM has fueled research regarding their implication on systemic therapy in WM. In a rapidly advancing field of targeted therapies, the treatment options for patients with WM are expanding as researchers continue to uncover and harness the survival pathways active in this hematologic malignancy.
Authors: Jorge J Castillo; Lian Xu; Joshua N Gustine; Andrew Keezer; Kirsten Meid; Toni E Dubeau; Xia Liu; Maria G Demos; Amanda Kofides; Nicholas Tsakmaklis; Jiaji G Chen; Manit Munshi; Maria L Guerrera; Gloria G Chan; Christopher J Patterson; Guang Yang; Zachary R Hunter; Steven P Treon Journal: Br J Haematol Date: 2019-07-03 Impact factor: 6.998
Authors: Xinfang Yu; Wei Li; Qipan Deng; Ling Li; Eric D Hsi; Ken H Young; Mingzhi Zhang; Yong Li Journal: Cancer Res Date: 2018-04-27 Impact factor: 12.701
Authors: Steven P Treon; Christina K Tripsas; Kirsten Meid; Diane Warren; Gaurav Varma; Rebecca Green; Kimon V Argyropoulos; Guang Yang; Yang Cao; Lian Xu; Christopher J Patterson; Scott Rodig; James L Zehnder; Jon C Aster; Nancy Lee Harris; Sandra Kanan; Irene Ghobrial; Jorge J Castillo; Jacob P Laubach; Zachary R Hunter; Zeena Salman; Jianling Li; Mei Cheng; Fong Clow; Thorsten Graef; M Lia Palomba; Ranjana H Advani Journal: N Engl J Med Date: 2015-04-09 Impact factor: 91.245
Authors: Andrew H Lipsky; Mohammed Z H Farooqui; Xin Tian; Sabrina Martyr; Ann M Cullinane; Khanh Nghiem; Clare Sun; Janet Valdez; Carsten U Niemann; Sarah E M Herman; Nakhle Saba; Susan Soto; Gerald Marti; Gulbu Uzel; Steve M Holland; Jay N Lozier; Adrian Wiestner Journal: Haematologica Date: 2015-10-01 Impact factor: 9.941
Authors: Jennifer A Woyach; Richard R Furman; Ta-Ming Liu; Hatice Gulcin Ozer; Marc Zapatka; Amy S Ruppert; Ling Xue; Daniel Hsieh-Hsin Li; Susanne M Steggerda; Matthias Versele; Sandeep S Dave; Jenny Zhang; Ayse Selen Yilmaz; Samantha M Jaglowski; Kristie A Blum; Arletta Lozanski; Gerard Lozanski; Danelle F James; Jacqueline C Barrientos; Peter Lichter; Stephan Stilgenbauer; Joseph J Buggy; Betty Y Chang; Amy J Johnson; John C Byrd Journal: N Engl J Med Date: 2014-05-28 Impact factor: 91.245
Authors: Joshua N Gustine; Lian Xu; Nicholas Tsakmaklis; Maria G Demos; Amanda Kofides; Jiaji G Chen; Xia Liu; Manit Munshi; Maria Luisa Guerrera; Gloria G Chan; Christopher J Patterson; Andrew Keezer; Kirsten Meid; Toni Dubeau; Guang Yang; Zachary R Hunter; Steven P Treon; Jorge J Castillo Journal: Blood Adv Date: 2019-10-08
Authors: Mark Bustoros; Romanos Sklavenitis-Pistofidis; Prashant Kapoor; Chia-Jen Liu; Efstathios Kastritis; Saurabh Zanwar; Geoffrey Fell; Jithma P Abeykoon; Kalvis Hornburg; Carl Jannes Neuse; Catherine R Marinac; David Liu; Jenny Soiffer; Maria Gavriatopoulou; Cody Boehner; Joseph M Cappuccio; Henry Dumke; Kaitlen Reyes; Robert J Soiffer; Robert A Kyle; Steven P Treon; Jorge J Castillo; Meletios A Dimopoulos; Stephen M Ansell; Lorenzo Trippa; Irene M Ghobrial Journal: J Clin Oncol Date: 2019-04-16 Impact factor: 44.544
Authors: K V Argyropoulos; R Vogel; C Ziegler; G Altan-Bonnet; E Velardi; M Calafiore; A Dogan; M Arcila; M Patel; K Knapp; C Mallek; Z R Hunter; S P Treon; M R M van den Brink; M L Palomba Journal: Leukemia Date: 2016-02-12 Impact factor: 11.528